More than 10,000 patients have now received the world’s smallest pacemaker.
Minneapolis, Minn., October 9, 2017 – The number of patients receiving implants of Micra™, the world’s smallest pacemaker, is growing at a fast pace.
Worldwide, more than 10,000 patients in 40 countries are now receiving pacing therapy from a Micra device. Micra transcatheter pacing system (TPS) passed the 6,000 patient mark, in 30 countries, in April of 2017. The 10,000 patient milestone comes just two-and-a-half years after Micra TPS received CE Mark in Europe, and 18 months after FDA approval in the United States.
Micra TPS is revolutionary for a number of reasons: It’s about one-tenth the size of a traditional pacing device, making it the smallest pacemaker in the world; it is implanted directly into the right ventricle of the heart, typically through the femoral vein, rather than surgically implanted in the chest; and it doesn’t require the use of leads, or wires that connect traditional pacemakers to the heart. Surgeons receive specific training on how to implant the device.
Mary Lou Trejo, of Columbus, Ohio, was among the first in the United States to receive a Micra device. The miniaturized pacemaker was in clinical trials at the time of her procedure. Three-and-a-half years later, she says she’s doing well.“I feel great,” she said in May of 2017. “My biggest news is that I started a new decade.” (She recently turned 80 years old). Learn more about Mary Lou and find out what her doctors say about Micra TPS.
In June of 2017, a functioning Micra pacemaker was launched into space as part of a high school student’s science project. Initial interrogation of the device showed it still operating the way engineers had designed.
Micra TPS was the result of eight years of development by Medtronic scientists, engineers and researchers, working to miniaturize medical devices.
Micra Model MC1VR01 is indicated for patients with:
Rate-responsive pacing is indicated to provide increased heart rate appropriate to increasing levels of activity.
Micra Model MC1VR01 is contraindicated for patients who have the following types of medical devices implanted: an implanted device that would interfere with the implant of the Micra device in the judgment of the implanting physician, an implanted inferior vena cava filter, a mechanical tricuspid valve, or an implanted cardiac device providing active cardiac therapy that may interfere with the sensing performance of the Micra device.
The device is contraindicated for patients who have the following conditions:femoral venous anatomy unable to accommodate a 7.8 mm (23 French) introducer sheath or implant on the right side of the heart (for example, due to obstructions or severe tortuosity), morbid obesity that prevents the implanted device from obtaining telemetry communication within ≤12.5 cm (4.9 in), or known intolerance to the materials listed in the Instruction for Use, or to heparin, or sensitivity to contrast media that cannot be adequately premedicated.
Steroid use – Do not use in patients for whom a single dose of 1.0 mg of dexamethasone acetate cannot be tolerated.
Warnings and precautions
End of Service (EOS) – When the EOS condition is met, the clinician has the option of permanently programming the device to Off and leaving it in the heart, or retrieving the device, provided the device has not yet become encapsulated. Removal of the Micra device after it has become encapsulated may be difficult because of the development of fibrotic tissue. If removal of the device is required, it is recommended that the removal be performed by a clinician who has expertise in the removal of implanted leads.
MRI conditions for use – Before an MRI scan is performed on a patient implanted with the Micra device, the cardiology and radiology professionals involved in this procedure must understand the requirements specific to their tasks as defined in the device manuals.
Rate-responsive mode may not be appropriate for patients who cannot tolerate pacing rates above the programmed Lower Rate. Asynchronous VVIR pacing with sinus rhythm may not be appropriate when competitive pacing is considered undesirable or causes symptoms of pacemaker syndrome. The patient’s age and medical condition should be considered by physicians and patients as they select the pacing system, mode of operation, and implant technique best suited to the individual.
Precautions should be taken before administering anticoagulant agents, antiplatelet agents, or contrast media in patients with known hypersensitivity to these agents.
The use of deactivated Micra devices in situ and an active Micra device, or an active transvenous pacemaker or defibrillator, has not been clinically tested to determine whether EMI or physical interaction is clinically significant. Bench testing supports that implantation of an active Micra device, or an active transvenous pacemaker or defibrillator, next to an inactivated Micra device is unlikely to cause EMI or physical interaction. Post-approval studies are planned to characterize risks of co-implanted, deactivated Micra devices. Currently recommended end of device life care for a Micra device may include the addition of a replacement device with or without explantation of the Micra device, which should be turned off.
Potential complications include, but are not limited to, toxic/allergic reaction, oversensing, acceleration of tachycardia, myocardial infarction and surgical complications such as cardiac perforation, pericardial effusion, cardiac tamponade, death, device embolization, access site hematoma and AV fistulae, vessel spasm, infection, inflammation, and thrombosis.
See the device manuals for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, MRI conditions for use, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.